The field of nanomedicine is a complex and rapidly growing scientific domain. Nanomedicine encompasses a large and diverse number of pharmaceutical formulations including liposomes, micelles, nanoparticles and polymer-drug conjugates. Pharmacists will be provided with a view of the landscape of nanomedicines, critical research gaps and implications for patient-safety and therapeutic efficacy.
SPEAKERS
Tamer Elbayoumi, PhD, MS, RPh, is a professor of pharmaceutical sciences. He completed his Fellowship at the Center of Pharmaceutical Biotechnology and Nanomedicine after receiving his Ph.D. in Pharmaceutical Sciences from Northeastern University, Boston. Before joining Midwestern University, he worked as senior formulation research scientist at Atrium Medical/ Getinge Corp. Dr. Elbayoumi has authored numerous publications, focusing on nanomedicines and targeted nanocarrier delivery systems in the areas of translational cardiovascular therapy, investigational cancer chemotherapy, and diagnostic imaging.
John B. Hertig, PharmD, MS, CPPS, is associate professor of pharmacy practice in the Butler University College of Pharmacy and Health Sciences. Dr. Hertig lectures around the world and publishes on a variety of patient safety, leadership, administration, and health policy topics. His extensive research program is designed to enhance the safety of the medication use process, while using evidence to inform patient advocacy efforts. Dr. Hertig is a Member of the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee. He holds other national and international appointments, including with the International Pharmaceutical Federation and as President of the Board of Directors for the Alliance for Safe Online Pharmacies.
Elizabeth (Liz) Shlom, PharmD, MBA, BCPS, is vice president, Acurity Clinical Pharmacy Program at Premier, Inc. In her role at Premier, Liz coordinates monthly ACPE-accredited educational forums, a weekly newsletter, drug information research assistance, membership surveys and website-based publications on clinically relevant topics including cost-saving initiatives and drug shortage alternatives. She served as NYSCHP President, NYS Delegate to the ASHP House of Delegates, and has served on the ASHP Council of Public Policy, and is currently on the Emerging Sciences Section Advisory Group.